125 related articles for article (PubMed ID: 38199382)
1. Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials.
Lynch C; Korpics MC; Katipally RR; Wu T; Bestvina CM; Pitroda S; Chmura SJ; Juloori A
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1519-1530. PubMed ID: 38199382
[TBL] [Abstract][Full Text] [Related]
2. Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasis.
Lee E; Chen X; LeCompte MC; Kleinberg LR; Hales RK; Voong KR; Forde PM; Brahmer JR; Markowski MC; Lipson EJ; Lee SH; Bydon A; Lo SL; Lubelski D; Redmond KJ
J Neurosurg Spine; 2023 Aug; 39(2):278-286. PubMed ID: 37148233
[TBL] [Abstract][Full Text] [Related]
3. Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Zhu KK; Wei JL; Xu YH; Li J; Rao XR; Xu YZ; Xing BY; Zhang SJ; Chen LC; Dong XR; Zhang S; Li ZY; Liu CW; Meng R; Wu G
Curr Med Sci; 2023 Apr; 43(2):344-359. PubMed ID: 37002471
[TBL] [Abstract][Full Text] [Related]
4. Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis.
Tian S; Switchenko JM; Buchwald ZS; Patel PR; Shelton JW; Kahn SE; Pillai RN; Steuer CE; Owonikoko TK; Behera M; Curran WJ; Higgins KA
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):304-313. PubMed ID: 31982496
[TBL] [Abstract][Full Text] [Related]
5. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T
Front Immunol; 2021; 12():651086. PubMed ID: 34248939
[TBL] [Abstract][Full Text] [Related]
6. Dosimetric analysis of liver toxicity after liver metastasis stereotactic body radiation therapy.
Barry A; McPartlin A; Lindsay P; Wang L; Brierley J; Kim J; Ringash J; Wong R; Dinniwell R; Craig T; Dawson LA
Pract Radiat Oncol; 2017; 7(5):e331-e337. PubMed ID: 28442242
[TBL] [Abstract][Full Text] [Related]
7. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases.
Rusthoven KE; Kavanagh BD; Cardenes H; Stieber VW; Burri SH; Feigenberg SJ; Chidel MA; Pugh TJ; Franklin W; Kane M; Gaspar LE; Schefter TE
J Clin Oncol; 2009 Apr; 27(10):1572-8. PubMed ID: 19255321
[TBL] [Abstract][Full Text] [Related]
8. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
9. Two-institution results of Stereotactic Body Radiation Therapy (SBRT) for treating adrenal gland metastases from liver cancer.
Xu B; Zhao X; Chen D; Zhao W; Wang X; Ding C; Yuan Z; Zhang H
BMC Cancer; 2023 Jan; 23(1):73. PubMed ID: 36681809
[TBL] [Abstract][Full Text] [Related]
10. Additional chemotherapy improved local control and overall survival after stereotactic body radiation therapy for patients with oligo-recurrence.
Nakamura M; Hashimoto N; Mayahara H; Uezono H; Harada A; Nishikawa R; Matsuo Y; Kawaguchi H; Nishimura H
Radiat Oncol; 2018 Apr; 13(1):75. PubMed ID: 29688858
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Adverse Radiation Effect in Brain Metastasis Patients Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy.
Helis CA; Hughes RT; Glenn CW; Lanier CM; Masters AH; Dohm A; Ahmed T; Ruiz J; Triozzi P; Gondal H; Cramer CK; Tatter SB; Laxton AW; Xing F; Lo HW; Su J; Watabe K; Wang G; Whitlow CT; Chan MD
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):295-303. PubMed ID: 32615262
[TBL] [Abstract][Full Text] [Related]
12. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review.
Rodríguez Plá M; Dualde Beltrán D; Ferrer Albiach E
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769050
[No Abstract] [Full Text] [Related]
14. Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases.
Shahi J; Poon I; Ung YC; Tsao M; Bjarnason GA; Malik NH; Zhang L; Louie AV; Cheung P
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):764-774. PubMed ID: 33115687
[TBL] [Abstract][Full Text] [Related]
15. Single community-based institutional series of stereotactic body radiation therapy (SBRT) for treatment of liver metastases.
Anstadt EJ; Shumway R; Colasanto J; Grew D
J Gastrointest Oncol; 2019 Apr; 10(2):330-338. PubMed ID: 31032102
[TBL] [Abstract][Full Text] [Related]
16. Re-irradiation stereotactic body radiotherapy for spinal metastases: a multi-institutional outcome analysis.
Hashmi A; Guckenberger M; Kersh R; Gerszten PC; Mantel F; Grills IS; Flickinger JC; Shin JH; Fahim DK; Winey B; Oh K; John Cho BC; Létourneau D; Sheehan J; Sahgal A
J Neurosurg Spine; 2016 Nov; 25(5):646-653. PubMed ID: 27341054
[TBL] [Abstract][Full Text] [Related]
17. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
Kim S; Wuthrick E; Blakaj D; Eroglu Z; Verschraegen C; Thapa R; Mills M; Dibs K; Liveringhouse C; Russell J; Caudell JJ; Tarhini A; Markowitz J; Kendra K; Wu R; Chen DT; Berglund A; Michael L; Aoki M; Wang MH; Hamaidi I; Cheng P; de la Iglesia J; Slebos RJ; Chung CH; Knepper TC; Moran-Segura CM; Nguyen JV; Perez BA; Rose T; Harrison L; Messina JL; Sondak VK; Tsai KY; Khushalani NI; Brohl AS
Lancet; 2022 Sep; 400(10357):1008-1019. PubMed ID: 36108657
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Xie C; Duffy AG; Brar G; Fioravanti S; Mabry-Hrones D; Walker M; Bonilla CM; Wood BJ; Citrin DE; Gil Ramirez EM; Escorcia FE; Redd B; Hernandez JM; Davis JL; Gasmi B; Kleiner D; Steinberg SM; Jones JC; Greten TF
Clin Cancer Res; 2020 May; 26(10):2318-2326. PubMed ID: 31996388
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effects of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with lung cancer and brain metastases: a propensity score-matched analysis.
Yomo S; Oda K; Oguchi K
J Neurosurg; 2023 Dec; 139(6):1628-1637. PubMed ID: 37243558
[TBL] [Abstract][Full Text] [Related]
20. The RSSearch™ Registry: patterns of care and outcomes research on patients treated with stereotactic radiosurgery and stereotactic body radiotherapy.
Davis JN; Medbery C; Sharma S; Danish A; Mahadevan A
Radiat Oncol; 2013 Nov; 8():275. PubMed ID: 24274599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
